Any solid tumor
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| FDA (1) | dMMR | Any solid tumor | Dostarlimab | |
| FDA (1) HC (1) | v::NTRK1 | Any solid tumor | Entrectinib | |
| FDA (1) HC (1) | v::NTRK2 | Any solid tumor | Entrectinib | |
| FDA (1) HC (1) | v::NTRK3 | Any solid tumor | Entrectinib | |
| FDA (1) HC (1) | v::NTRK1 | Any solid tumor | Larotrectinib | |
| FDA (1) HC (1) | v::NTRK2 | Any solid tumor | Larotrectinib | |
| FDA (1) HC (1) | v::NTRK3 | Any solid tumor | Larotrectinib | |
| FDA (1) HC (1) | dMMR | Any solid tumor | Pembrolizumab | |
| FDA (1) HC (1) | MSI-H | Any solid tumor | Pembrolizumab | |
| FDA (1) | TMB-H (>= 10 mutations / Mb) | Any solid tumor | Pembrolizumab | |
| FDA (1) | v::NTRK1 | Any solid tumor | Repotrectinib | |
| FDA (1) | v::NTRK2 | Any solid tumor | Repotrectinib | |
| FDA (1) | v::NTRK3 | Any solid tumor | Repotrectinib | |
| FDA (1) | v::RET | Any solid tumor | Selpercatinib | |
| FDA (1) | HER2-positive | Any solid tumor | Trastuzumab deruxtecan |